

2025 Impact Report



— Charles D. Blanke, MD
Chair, SWOG Cancer Research Network

2025 has been memorable in so many ways, and this report highlights some key SWOG milestones and accomplishments from the year.

Coming to the close of our current grant cycles gives us a chance to take stock of SWOG's longer-term accomplishments as well. That accounting is impressive – check out "The Long View" below.

It has been an honor to lead SWOG over these years. I'm extraordinarily proud of what we have accomplished and the lives we've saved and improved. 2026 and beyond will see even more extraordinary SWOG achievements and impact. 

NCI National Clinical Trials Network

NCI Community Oncology Research Program

Our Data

8 SWOG trials activated 6 SWOG trials closed

32 clinical and translational concepts reviewed by leadership


24 requests for trial data granted

3,686 patients enrolled on all SWOG-run trials,
not counting screening registrations

81 journal articles published 42% published in high impact factor journals

73 oral or poster presentations made 23% of presentations were oral

52 new member sites



Our Highlights

Based on the results of S1826, the FDA granted priority review of an application for using the trial's nivolumab + AVD combination in untreated adult and pediatric classic Hodgkin lymphoma. An approval decision is expected by spring. Also in 2025: three-year follow-up data from S1826 confirmed the durability of the combination's benefit.



We celebrated the 25th anniversary of SWOG's flagship mentoring and training program for investigators – now known as the Leadership and Project Development (LEAP) course (formerly our Young/Early-Stage Investigator Training Course).

More than 130 researchers have completed the course, which has directly led to more than 50 SWOG clinical trials and has nurtured numerous SWOG leaders. Over the years, program graduates have been authors on more than 20,000 publications, which in turn have been cited more than half a million times.

Early in 2025, one recent program graduate, **Dr. Jonathan Sham**, activated the first clinical trial born and bred in SWOG's palliative care committee. S2408 asks whether the drug lanreotide can reduce the risk of pancreatic fistula following surgery for pancreatic cancer.



SWOG submitted applications for the next cycle of NCI grants to support our NCTN Network Operations Center (NOC) and Statistics & Data Management Center (SDMC). Our NOC grant earned an "outstanding" score, our SDMC grant an "exceptional."

We are now crafting our application for the next round of NCORP Research Base awards.

The Long View: Quantifying SWOG's grant cycles just ending (2018 – 2025)

>80 clinical trials launched

>700 peer-reviewed manuscripts published


>30,000 volunteers enrolled to our clinical trials

>600 new member sites welcomed

>600 research abstracts presented

We appointed **Dr. Raymond Osarogiagbon** as our first executive officer for community site engagement. He will work to boost the involvement of our community-based members in all stages of the development and conduct of SWOG trials.

We welcomed **Dr. Amrita Krishnan** as the new chair of our Barlogie-Salmon Myeloma Committee.



Patients whose non-small cell lung cancer has returned after chemo- and immuno-therapy

We reported initial results from our landmark S2302 Pragmatica-Lung trial. Although the study did not meet its primary endpoint, it was a resounding success as a model for leaner, faster clinical trials that are easier for our sites to open and conduct, and

more activations in 2026.



As always, the insights of our community are invaluable to our growth. I welcome the opportunity to connect and discuss our shared commitment to advancing research in the year ahead.

Jo Horn
President & CEO



HOPE BY THE NUMBERS 2025

\$2.7 MILLION
in funding approved
in support of SWOG
research



182
Travelers funded
to attend group
meetings



9
New peer-reviewed
research proposals
awarded

